We are monitoring the impact of COVID-19 on Cytokine Based Therapies and Inhibitors Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 7991
Share on
Share on

Global Cytokine Based Therapies and Inhibitors Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Type, Therapeutic Application & Region - Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 7991
Pages: 175

Cytokine Based Therapies and Inhibitors Market Size (2021 to 2026)

The size of the global cytokine-based therapies and inhibitors market is estimated to grow at a healthy CAGR during the forecast period.

Cytokines are the molecular messengers that allow communication with the immune system cells to generate a coordinated, robust but self-limited response to the targeted antigen. Cytokines provide various benefits; unlike in chemical drugs, a specific protein that mediates the inflammatory process can be inhibited.  Cytokine inhibitors include antagonists, soluble receptors, cytokine binding proteins, and the cytokine that blocks other cytokines. The treatment for immune-mediated medical illnesses, including cancer and viral infections, can be done using Immunomodulatory, anti-viral, antiproliferative properties, cytokine interferon-alpha interleukin (IL).

The cytokine-based therapies can provide novel treatments for cancer, autoimmune diseases, and many types of infectious diseases. Various factors have limited the clinical potential of cytokines as drugs. FDA   partnership was made with the New York Academy of Sciences to host a forum to discuss practical ways to harness the clinical potential of cytokines and cytokine antagonists as therapeutic agents.

MARKET DRIVERS:

Cytokine-based therapies have the potential to provide treatments for autoimmune diseases and cancer. Intercellular messengers activate signaling pathways in virtually all cell types. Rising research and development for understanding the mechanics and technological advancements in the immunological and therapeutics applications are anticipated to propel the market growth of the cytokine-based Therapies and Inhibitors Market. Increasing interest in harnessing the immune system to eradicate cancer will crease demand for the market. Vast signaling networks to develop cancer treatments are expected to raise market growth. Several animal tumor model studies have displayed that cytokines have a broad anti-tumor activity translated into several cytokine-based approaches for cancer therapy which is expected to drive the market growth. Cytokines are finding growing acceptance in cancer therapy all over the world. 

MARKET RESTRAINTS:

The Cytokine Based Therapies and Inhibitors Market has some restraining factors that are restraining market growth, such as scarcity of skilled professionals for cytokine treatments for autoimmune diseases and cancer across the world; high cost of therapies are expected to impede the market growth.

Impact of COVID-19 on Cytokine Based Therapies and Inhibitors Market:

The covid-19 is a global pandemic, which was first identified in Wuhan, China. The world health organization announced the COVID-19 as the emergence of healthcare. It is an infectious disease, spread quickly from person to person. All the governments had declared nationwide lockdown and a ban on transportation and flights to control the spread.

COVID 19 disrupted the global economy in an unprecedented way. Many country's government authorities had imposed lockdown restrictions that disturbed the supply chain and manufacturing units with the coronavirus's surging cases.

However, the current evidence represents that severely ill patients tend to have a high concentration of proinflammatory cytokines. The high level of cytokines also shows a poor prognosis in COVID-19. Also, excessive infiltration of proinflammatory cells, including macrophages and T-helper 17 cells, has been found in lung tissues of coronavirus patients by post-mortem examination. As per the reports, cytokine storms may contribute to the mortality of COVID-19.  The cytokines-based therapies and inhibitors market is anticipated to witness higher growth in the forecast period.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Type, Therapeutic Application, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

This research report on the global cytokine-based therapies and inhibitors market has been segmented and sub-segmented based on the type, therapeutic application, and region.

Cytokine Based Therapies and Inhibitors Market – By Type:

  • Interleukins            
  • Tumor necrosis factor        
  • Epidermal growth factor   
  • Interferon               
  • Chemokine    

Based on the type, the interleukins segment is expected to dominate the global cytokine-based therapies and inhibitors market during the forecast period. Interleukins are a group of cytokines that were first seen to be expressed by white blood cells. Interleukins regulate cell growth, differentiation, and mobility, are essential in stimulating immune responses like inflammation. The increasing global prevalence of autoimmune disorders, increasing geriatric population, and advanced technologies in novel interleukins inhibitors are projected to increase the market growth.

Cytokine Based Therapies and Inhibitors Market – By Therapeutic Application:

  • Inflammatory and immune disorders          
  • Cancer and malignancies   
  • Infectious diseases              
  • Others      

Based on the therapeutic application, the inflammatory and immune disorders segment accounted for the largest share in the global market during the forecast period. The sign of an autoimmune disease is inflammation which causes redness, pain, and swelling. The disorders also have flare-ups when they get worse and in remission. An increase in the autoimmune system incidence, rise in the adoption of autoimmune disease therapeutics, and growing R&D activities to develop ideal therapeutics are the major driving factors of the inflammatory and immune disorders market.

Cytokine Based Therapies and Inhibitors Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Geographically, North America leads the global cytokine-based therapies and inhibitors market due to many companies in Cytokine Based Therapies and Inhibitors and increasing government investments. The North American Cytokine Based Therapies and Inhibitors Market growth is majorly driven by the factors such as the increasing prevalence of cancer. According to the American cancer society, it was estimated there were 1,762,450 new cancer cases and 606,880 diagnosed cancer deaths in the United States, which are anticipated to rise in the future. Moreover, increasing R&D activities of cancer therapies with lesser side effects are expected to create demand for cytokine-based treatments through which market expansion is possible.

In 2019, the European market had accounted for a substantial share globally and was estimated to register healthy CAGR during the market forecast period. The market growth can be increased by the factors such as growing interest among the people in harnessing the immune system to eradicate cancer.

The Asia Pacific is the fastest-growing market segment due to the growing awareness and increasing collaborations with western companies in China and the well-established biotechnology industries in Japan.

The Latin American market is expected to have steady growth with an increasing compound annual growth rate (CAGR). The players are technological advancements in immunological and therapeutics applications and are anticipated to propel cytokine-based market growth.

Middle East Africa held a moderate share of the Cytokine Based Therapies and Inhibitors Market. The market had a portion of the global market in 2020. However, Middle East Africa is projected to increase its growth during the forecast period.

KEY MARKET PARTICIPANTS:

Some of the prominent companies leading the global cytokine-based therapies and inhibitors market profiled in this report are GlaxoSmithKline LLC, AbbVie Inc., Eli Lilly and Company, Genentech, Inc., Immunochemistry Technologies LLC, Roche Diagnostics, Novartis, Merck Sharp & Dohme Corp., Johnson & Johnson, and Amgen Inc.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Type                              

                                5.1.1 Introduction           

                                5.1.2 Interleukins            

                                5.1.3 Tumor necrosis factor        

                                5.1.4 Epidermal growth factor   

                                5.1.5 Interferon               

                                5.1.6 Chemokine             

                                5.1.7  Y-o-Y Growth Analysis, By Type    

                                5.1.8  Market Attractiveness Analysis, By Type  

                                5.1.9  Market Share Analysis, By Type    

                5.2 Therapeutic Application                        

                                5.2.1 Introduction           

                                5.2.2 Inflammatory and immune disorders          

                                5.2.3 Cancer and malignancies   

                                5.2.4 Infectious diseases              

                                5.2.5 Others      

                                5.2.6 Y-o-Y Growth Analysis, By Therapeutic Application               

                                5.2.7 Market Attractiveness Analysis, By Therapeutic Application             

                                5.2.8 Market Share Analysis, By Therapeutic Application               

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Type

                                                6.1.3.3 By Therapeutic Application

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Type

                                                6.1.4.3 By Therapeutic Application

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Type

                                                6.1.5.3 By Therapeutic Application

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 GlaxoSmithKline LLC                               

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 AbbVie Inc.                 

                8.3 Eli Lilly and Company                              

                8.4 Genentech, Inc                         

                8.5 Immunochemistry Technologies LLC                               

                8.6 Roche Diagnostics                    

                8.7 Novartis                       

                8.8 Merck Sharp & Dohme Corp                               

                8.9 Johnson & Johnson                 

                8.10 Amgen Inc                

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Product and Application along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  •  to provide both individuals and organizations a strong financial foothold in the marketInvestment opportunitiesExpertly devised analyst overview along with 
  •  
  1. Global Cytokine Based Therapies and Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  2. Global Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  3. Global Interleukins Market, By Region, From 2021 to 2026 (USD Million)
  4. Global Tumor necrosis factor Market, By Region, From 2021 to 2026 (USD Million)
  5. Global Epidermal growth factor Market, By Region, From 2021 to 2026 (USD Million)
  6. Global Interferon Market, By Region, From 2021 to 2026 (USD Million)
  7. Global Chemokine Market, By Region, From 2021 to 2026 (USD Million)
  8. Global Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  9. Global Inflammatory and immune disorders Market, By Region, From 2021 to 2026 (USD Million)
  10. Global Cancer and malignancies Market, By Region, From 2021 to 2026 (USD Million)
  11. Global Infectious diseases Market, By Region, From 2021 to 2026 (USD Million)
  12. Global Others Market, By Region, From 2021 to 2026 (USD Million)
  13. North America Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  14. North America Interleukins Market, By Region, From 2021 to 2026 (USD Million)
  15. North America Tumor necrosis factor Market, By Region, From 2021 to 2026 (USD Million)
  16. North America Epidermal growth factor Market, By Region, From 2021 to 2026 (USD Million)
  17. North America Interferon Market, By Region, From 2021 to 2026 (USD Million)
  18. North America Chemokine Market, By Region, From 2021 to 2026 (USD Million)
  19. North America Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  20. North America Inflammatory and immune disorders Market, By Region, From 2021 to 2026 (USD Million)
  21. North America Cancer and malignancies Market, By Region, From 2021 to 2026 (USD Million)
  22. North America Infectious diseases Market, By Region, From 2021 to 2026 (USD Million)
  23. North America Others Market, By Region, From 2021 to 2026 (USD Million)
  24. United States Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  25. United States Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  26. Canada Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  27. Canada Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  28. Europe Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  29. Europe Interleukins Market, By Region, From 2021 to 2026 (USD Million)
  30. Europe Tumor necrosis factor Market, By Region, From 2021 to 2026 (USD Million)
  31. Europe Epidermal growth factor Market, By Region, From 2021 to 2026 (USD Million)
  32. Europe Interferon Market, By Region, From 2021 to 2026 (USD Million)
  33. Europe Chemokine Market, By Region, From 2021 to 2026 (USD Million)
  34. Europe Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  35. Europe Inflammatory and immune disorders Market, By Region, From 2021 to 2026 (USD Million)
  36. Europe Cancer and malignancies Market, By Region, From 2021 to 2026 (USD Million)
  37. Europe Infectious diseases Market, By Region, From 2021 to 2026 (USD Million)
  38. Europe Others Market, By Region, From 2021 to 2026 (USD Million)
  39. U.K. Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  40. U.K. Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  41. Germany Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  42. Germany Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  43. France Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  44. France Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  45. Italy Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  46. Italy Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  47. Spain Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  48. Spain Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  49. Asia Pacific Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  50. Asia Pacific Interleukins Market, By Region, From 2021 to 2026 (USD Million)
  51. Asia Pacific Tumor necrosis factor Market, By Region, From 2021 to 2026 (USD Million)
  52. Asia Pacific Epidermal growth factor Market, By Region, From 2021 to 2026 (USD Million)
  53. Asia Pacific Interferon Market, By Region, From 2021 to 2026 (USD Million)
  54. Asia Pacific Chemokine Market, By Region, From 2021 to 2026 (USD Million)
  55. Asia Pacific Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  56. Asia Pacific Inflammatory and immune disorders Market, By Region, From 2021 to 2026 (USD Million)
  57. Asia Pacific Cancer and malignancies Market, By Region, from 2021 to 2026 (USD Million)
  58. Asia Pacific Infectious diseases Market, By Region, From 2021 to 2026 (USD Million)
  59. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Million)
  60. Japan Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  61. Japan Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  62. China Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  63. China Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  64. India Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  65. India Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  66. Australia Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  67. Australia Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  68. South Korea Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  69. South Korea Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  70. Latin America Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  71. Latin America Interleukins Market, By Region, From 2021 to 2026 (USD Million)
  72. Latin America Tumor necrosis factor Market, By Region, From 2021 to 2026 (USD Million)
  73. Latin America Epidermal growth factor Market, By Region, From 2021 to 2026 (USD Million)
  74. Latin America Interferon Market, By Region, From 2021 to 2026 (USD Million)
  75. Latin America Chemokine Market, By Region, From 2021 to 2026 (USD Million)
  76. Latin America Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  77. Latin America Inflammatory and immune disorders Market, By Region, From 2021 to 2026 (USD Million)
  78. Latin America Cancer and malignancies Market, By Region, From 2021 to 2026 (USD Million)
  79. Latin America Infectious diseases Market, By Region, From 2021 to 2026 (USD Million)
  80. Latin America Others Market, By Region, From 2021 to 2026 (USD Million)
  81. Brazil Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  82. Brazil Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  83. Argentina Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  84. Argentina Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  85. Mexico Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  86. Mexico Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  87. Rest of Latin America Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  88. Rest of Latin America Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  89. Middle East and Africa Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  90. Middle East and Africa Interleukins Market, By Region, From 2021 to 2026 (USD Million)
  91. Middle East and Africa Tumor necrosis factor Market, By Region, From 2021 to 2026 (USD Million)
  92. Middle East and Africa Epidermal growth factor Market, By Region, From 2021 to 2026 (USD Million)
  93. Middle East and Africa Interferon Market, By Region, From 2021 to 2026 (USD Million)
  94. Middle East and Africa Chemokine Market, By Region, From 2021 to 2026 (USD Million)
  95. Middle East and Africa Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  96. Middle East and Africa Inflammatory and immune disorders Market, By Region, From 2021 to 2026 (USD Million)
  97. Middle East and Africa Cancer and malignancies Market, By Region, From 2021 to 2026 (USD Million)
  98. Middle East and Africa Infectious diseases Market, By Region, From 2021 to 2026 (USD Million)
  99. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Million)
  100. Middle East Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  101. Middle East Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)
  102. Africa Cytokine Based Therapies and Inhibitors Market, By Type, From 2021 to 2026 (USD Million)
  103. Africa Cytokine Based Therapies and Inhibitors Market, By Therapeutic Application, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample